Cyclo Therapeutics (CYTH) Stock Price, News & Analysis

Company Overview

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Key Stats

• Today's Range: $0.72 to $0.72
• 50-Day Range: $0.72 to $0.72
• 52-Week Range: $0.55 to $1.45
• Volume: N/A
• Average Volume: 585,177 shs
• Market Capitalization: $23.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYTH Stock Analysis - Frequently Asked Questions

How were Cyclo Therapeutics' earnings last quarter?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) posted its earnings results on Thursday, August, 15th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.07. The firm earned $0.12 million during the quarter, compared to analyst estimates of $0.40 million.

What other stocks do shareholders of Cyclo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclo Therapeutics investors own include Rolls-Royce Holdings PLC (RYCEY), Blink Charging (BLNK), Ford Motor (F), Alphabet (GOOG), Cassava Sciences (SAVA), Zoom Communications (ZM) and Fisker (FSR).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 9/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYTH
• CIK: 922247
• Web: www.ctd-holdings.com
• Phone: (386) 418-8060
• Fax: 321-244-8351
• Employees: 9
• Year Founded: 1990

Profitability

• EPS (Trailing Twelve Months): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.06 million
• Net Margins: -2,847.19%
• Pretax Margin: -2,847.30%
• Return on Equity: N/A
• Return on Assets: -307.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.17
• Quick Ratio: 0.16

Sales & Book Value

• Annual Sales: $870.73 thousand
• Price / Sales: 27.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.21 per share
• Price / Book: 3.43

Miscellaneous

• Outstanding Shares: 32,919,000
• Free Float: 23,116,000
• Market Cap: $23.72 million
• Optionable: No Data
• Beta: -0.57